Beth Karlan
#98,164
Most Influential Person Now
American gynecologic oncologist
Beth Karlan's AcademicInfluence.com Rankings
Beth Karlanphilosophy Degrees
Philosophy
#6049
World Rank
#9013
Historical Rank
Logic
#3241
World Rank
#4368
Historical Rank
Download Badge
Philosophy
Beth Karlan's Degrees
- Doctorate Medicine Harvard University
Why Is Beth Karlan Influential?
(Suggest an Edit or Addition)According to Wikipedia, Beth Young Karlan is an American gynecologic oncologist. In 2008, she was named editor-in-chief of the medical journals Gynecologic Oncology and Gynecologic Oncology Reports. In 2012, Karlan was appointed by the White House to serve on the National Cancer Advisory Board, and in 2015, she was elected to the National Academy of Medicine.
Beth Karlan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
- Integrated genomic characterization of endometrial carcinoma (2013) (3708)
- The Immune Landscape of Cancer (2018) (2766)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers (2008) (979)
- Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk (2015) (838)
- Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
- Integrated genomic and molecular characterization of cervical cancer (2017) (762)
- Ovarian cancer: screening, treatment, and followup. (1995) (579)
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
- Salpingo-Oophorectomy and the Risk Of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation (2006) (566)
- Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. (2012) (544)
- Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
- Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. (2014) (506)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. (2011) (500)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. (2008) (466)
- Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. (2002) (464)
- Improved survival in women with BRCA‐associated ovarian carcinoma (2003) (453)
- Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas (1999) (450)
- Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. (2003) (447)
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2011) (447)
- Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. (2010) (441)
- OVARIAN CANCER (2016) (439)
- Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. (2004) (424)
- Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk (2013) (405)
- Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. (1999) (398)
- Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. (2005) (398)
- Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. (2015) (390)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Adverse health outcomes in women exposed in utero to diethylstilbestrol. (2011) (365)
- A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population (2010) (357)
- GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer (2013) (350)
- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021) (346)
- BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. (2000) (334)
- Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. (2015) (333)
- Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. (2012) (298)
- Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. (1999) (287)
- Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer (2008) (280)
- Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2009) (277)
- A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer (2013) (265)
- Common variants at 19p13 are associated with susceptibility to ovarian cancer (2010) (262)
- Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. (2007) (257)
- Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. (2006) (253)
- Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. (2007) (243)
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer (2017) (237)
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. (2014) (236)
- DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. (1996) (234)
- Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. (2007) (232)
- Discovery and Preclinical Validation of Salivary Transcriptomic and Proteomic Biomarkers for the Non-Invasive Detection of Breast Cancer (2010) (223)
- Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. (2012) (219)
- Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers (2017) (211)
- Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations (2018) (206)
- 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. (2006) (200)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. (2010) (196)
- Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. (2010) (193)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. (2004) (184)
- Differential gene expression between normal and tumor-derived ovarian epithelial cells. (2000) (179)
- ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. (2014) (177)
- The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. (2016) (176)
- Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
- PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
- A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer (2002) (171)
- Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2017) (171)
- Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations (2015) (171)
- ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes (2006) (171)
- BRCA-Mutation–Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype? (2005) (168)
- Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer (2013) (167)
- Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway (2010) (166)
- Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer (2014) (163)
- Evaluation of MCF10A as a Reliable Model for Normal Human Mammary Epithelial Cells (2015) (162)
- Plasma cell‐free DNA in ovarian cancer (2010) (151)
- Periostin Secreted by Epithelial Ovarian Carcinoma Is a Ligand for V 3 and V 5 Integrins and Promotes Cell Motility 1 (2002) (149)
- Prognostic DNA Methylation Biomarkers in Ovarian Cancer (2006) (147)
- Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. (2016) (146)
- YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14 (2012) (144)
- Platelets reduce anoikis and promote metastasis by activating YAP1 signaling (2017) (141)
- Impact of beta blockers on epithelial ovarian cancer survival. (2011) (140)
- Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism (2014) (130)
- Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study (2013) (124)
- BRCA1 germline mutations may be associated with reduced ovarian reserve. (2014) (123)
- Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 (2016) (122)
- Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. (2013) (117)
- BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. (2006) (116)
- Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. (2001) (116)
- Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo (2008) (114)
- Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. (1999) (113)
- ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. (2006) (112)
- DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (112)
- FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer (2006) (111)
- Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2019) (110)
- Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 (2013) (110)
- A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission (2012) (108)
- Gene expression in epithelial ovarian carcinoma (2002) (105)
- Where are we now and where are we going? (1995) (105)
- The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. (2013) (103)
- Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (103)
- Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers (2018) (103)
- Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas (2005) (102)
- Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. (1993) (102)
- Periostin promotes ovarian cancer angiogenesis and metastasis. (2010) (102)
- Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (2011) (101)
- Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. (2009) (101)
- Quality of care in advanced ovarian cancer: the importance of provider specialty. (2010) (100)
- Cancer incidence in a population of Jewish women at risk of ovarian cancer. (2002) (98)
- Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer (2007) (97)
- Ovulation induction, infertility, and ovarian cancer risk. (1996) (97)
- Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. (1995) (96)
- Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (95)
- Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers (2005) (93)
- Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer (2005) (92)
- Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. (2003) (92)
- Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers (2012) (92)
- Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS (2014) (89)
- HER‐2/neu, p53, and DNA Analyses as Prognosticators for Survival in Endometrial Carcinoma (1995) (86)
- A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. (2016) (86)
- Is the easier way ever the better way? (2011) (85)
- Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. (2016) (84)
- Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (84)
- Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. (2013) (83)
- The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. (2004) (83)
- Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (82)
- The Role of the HER-2/neu Oncogene in Gynecologic Cancers (1996) (82)
- Genome-wide significant risk associations for mucinous ovarian carcinoma (2015) (81)
- POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. (2014) (79)
- Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease. (1994) (78)
- Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA ) (2011) (78)
- International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation (2019) (78)
- Altered expression of transforming growth factor‐β ligands and receptors in primary and recurrent ovarian carcinoma (1999) (76)
- The CYP1A2 Genotype Modifies the Association Between Coffee Consumption and Breast Cancer Risk Among BRCA1 Mutation Carriers (2007) (76)
- BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
- Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. (2016) (76)
- Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers (2014) (75)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
- Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. (2007) (73)
- "Ovarian cancers: Evolving paradigms in research and care": Report from the Institute of Medicine. (2016) (72)
- Impact of statin therapy on survival in epithelial ovarian cancer. (2008) (72)
- ERCC5 is a novel biomarker of ovarian cancer prognosis. (2008) (71)
- Effect of obesity on survival in epithelial ovarian cancer (2007) (71)
- A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. (1993) (71)
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
- Ovarian cancer: the duplicity of CA125 measurement (2010) (69)
- Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors. (1999) (69)
- Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. (2011) (68)
- Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 (2002) (68)
- Shared heritability and functional enrichment across six solid cancers (2018) (67)
- The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. (1994) (65)
- FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival (2002) (65)
- Cyclin E as a potential therapeutic target in high grade serous ovarian cancer. (2016) (64)
- Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. (2017) (64)
- Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System (2014) (63)
- Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. (2016) (63)
- Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. (2003) (62)
- Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients (2011) (61)
- Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants (2020) (60)
- Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. (2016) (60)
- Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2012) (60)
- Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. (2010) (60)
- Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. (2013) (60)
- A highly sensitive chromogenic microtiter plate assay for plasminogen activators which quantitatively discriminates between the urokinase and tissue-type activators. (1987) (60)
- A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. (2011) (59)
- Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis (2011) (59)
- Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. (2010) (59)
- Generating longitudinal screening algorithms using novel biomarkers for disease. (2002) (59)
- Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (58)
- Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. (2018) (58)
- Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
- Secondary surgical cytoreduction for advanced epithelial ovarian cancer: Patient selection and review of the literature (1996) (58)
- Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. (2007) (58)
- Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers (2013) (57)
- Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers (2015) (57)
- ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. (2013) (57)
- Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers (2012) (56)
- The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing (2011) (56)
- Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. (2000) (56)
- Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin (2010) (55)
- Obesity-associated adipokines correlate with survival in epithelial ovarian cancer. (2012) (55)
- Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. (2001) (55)
- Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (55)
- A transcriptome-wide association study of high grade serous epithelial ovarian cancer identifies novel susceptibility genes and splice variants (2019) (54)
- Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study (2016) (54)
- Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers (2006) (54)
- Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers. (2010) (54)
- Splenectomy and surgical cytoreduction for ovarian cancer. (2000) (53)
- Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (53)
- A role for BRCA1 in uterine leiomyosarcoma. (2009) (53)
- Salpingectomy as a Means to Reduce Ovarian Cancer Risk (2015) (52)
- BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. (2010) (51)
- The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. (1994) (50)
- Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study (2018) (50)
- Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers (2007) (50)
- Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer (2015) (50)
- Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer (2012) (49)
- Super-Enhancer-Associated LncRNA UCA1 Interacts Directly with AMOT to Activate YAP Target Genes in Epithelial Ovarian Cancer (2019) (48)
- Sphingosine kinase 1 is required for TGF-β mediated fibroblast-to-myofibroblast differentiation in ovarian cancer (2015) (48)
- Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. (2010) (48)
- Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. (2007) (47)
- A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause (2012) (47)
- Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. (1999) (47)
- Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers (2012) (47)
- Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. (2010) (45)
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial (2014) (45)
- A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. (2018) (45)
- Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. (2015) (44)
- Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. (2006) (44)
- Functional domains of CCN1 (Cyr61) regulate breast cancer progression. (2008) (44)
- Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. (2013) (43)
- Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. (2007) (43)
- Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium (2017) (43)
- What is the role of reassessment laparoscopy in the management of gynecologic cancers in 1995? (1996) (42)
- Chemotherapy in epithelial ovarian cancer. (2002) (42)
- CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. (2011) (42)
- Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome (2012) (42)
- Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. (2014) (42)
- Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. (2017) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Xeroderma pigmentosum complementation group C single‐nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression‐free survival in advanced ovarian cancer (2012) (41)
- Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. (2016) (40)
- High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients (2016) (40)
- Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target (2008) (40)
- Genome-Wide Loss of Heterozygosity and Uniparental Disomy in BRCA1/2-Associated Ovarian Carcinomas (2008) (40)
- Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. (1994) (39)
- Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants (2022) (39)
- A human ovarian carcinoma murine xenograft model useful for preclinical trials. (2002) (39)
- Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. (2015) (39)
- PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. (2016) (39)
- Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (39)
- BRCA 1 Promoter Region Hypermethylation in Ovarian Carcinoma : A Population-based Study 1 (2000) (39)
- Ovarian cancer screening. The role of ultrasound in early detection (1995) (38)
- FOXC1 is a Critical Mediator of EGFR Function in Human Basal-like Breast Cancer (2014) (38)
- Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection (2012) (38)
- Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers (2015) (37)
- Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality (2011) (37)
- Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer (2020) (36)
- The Fragile Histidine Triad Gene: A Molecular Link Between Cigarette Smoking and Cervical Cancer (2005) (36)
- Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk (2015) (36)
- Foxc2 induces Wnt4 and Bmp4 expression during muscle regeneration and osteogenesis (2013) (36)
- AIB1 Polymorphisms Predict Aggressive Ovarian Cancer Phenotype (2005) (35)
- Molecular similarities between primary peritoneal and primary ovarian carcinomas (2003) (35)
- Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells: inhibition by glucocorticoids. (1988) (35)
- Ovarian cancer screening. (2003) (34)
- Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma? (2010) (34)
- Optimizing exosomal RNA isolation for RNA-Seq analyses of archival sera specimens (2018) (34)
- Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer (2016) (34)
- A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development. (2019) (34)
- Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT (2017) (33)
- Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (32)
- Reduced expression and growth inhibitory activity of the aging suppressor klotho in epithelial ovarian cancer. (2015) (32)
- Genetic factors in ovarian carcinoma (2001) (32)
- Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women (2014) (31)
- Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium (2015) (31)
- Too much, too late: Aggressive measures and the timing of end of life care discussions in women with gynecologic malignancies. (2014) (31)
- NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021 (2020) (31)
- Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN. (2016) (31)
- Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. (1994) (31)
- The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice (2007) (31)
- Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. (2009) (30)
- The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. (1997) (30)
- Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. (1993) (29)
- Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. (2018) (29)
- Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (29)
- High-throughput plasmid mini preparations facilitated by micro-mixing. (1996) (29)
- Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. (2003) (29)
- Comprar Danforth Obstetrics and Gynecology 10Ed | Ingrid E. Nygaard MD | 9780781769372 | Lippincott Williams & Wilkins (2008) (29)
- Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. (2010) (29)
- Treatment-Related Protein Biomarker Expression Differs between Primary and Recurrent Ovarian Carcinomas (2011) (28)
- Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. (1988) (28)
- Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. (2017) (28)
- Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. (2017) (28)
- Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. (2007) (28)
- An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers (2016) (28)
- Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. (2019) (27)
- Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. (1995) (27)
- Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. (1997) (27)
- Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE) (2020) (27)
- Comparison of Breast Cancer to Healthy Control Tissue Discovers Novel Markers with Potential for Prognosis and Early Detection (2010) (27)
- Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. (2004) (26)
- Predicting master transcription factors from pan-cancer expression data (2019) (26)
- The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study (2016) (26)
- History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium (2017) (26)
- Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC) (2015) (26)
- Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study (2015) (26)
- Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? (2017) (26)
- PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS (2010) (25)
- Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium (2020) (25)
- A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers. (2014) (25)
- An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (25)
- ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma. (2015) (25)
- Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. (1995) (25)
- Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA (2013) (24)
- The risk of ovarian cancer after treatment for infertility. (1996) (24)
- The prognostic significance of thrombocytosis in uterine papillary serous carcinomas. (2007) (24)
- Successful treatment of neuroendocrine small cell carcinoma of the cervix metastatic to regional lymph nodes. (1996) (23)
- A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. (2000) (23)
- Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. (2012) (23)
- Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations. (1987) (23)
- Incidence and management of edema associated with trebananib (AMG 386). (2013) (23)
- Allelotype of papillary serous peritoneal carcinomas. (2001) (23)
- Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival. (2013) (23)
- Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. (2019) (22)
- Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium (2017) (22)
- A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers (2012) (22)
- BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry (2019) (22)
- Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States) (2003) (22)
- Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer (2019) (22)
- Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome (2013) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Surgical intensive care unit care after ovarian cancer surgery: an analysis of indications. (1997) (21)
- MyD88 and TLR4 Expression in Epithelial Ovarian Cancer (2018) (21)
- Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data (2021) (21)
- The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers (2018) (21)
- Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk (2015) (21)
- No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews. (1998) (20)
- Hereditary ovarian cancer--assessing risk and prevention strategies. (2007) (20)
- The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (20)
- Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. (2008) (20)
- Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 (2016) (20)
- Screening for ovarian cancer: What are the optimal surrogate endpoints for clinical trials? (1995) (20)
- Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome (2014) (20)
- Recurrent ovarian carcinoma: is there a place for surgery? (2000) (20)
- Predictors of survival trajectories among women with epithelial ovarian cancer. (2019) (19)
- Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status (2005) (19)
- Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci (2017) (19)
- Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. (1994) (19)
- Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? (2010) (19)
- Lymphadenectomy's role in early endometrial cancer: prognostic or therapeutic? (2008) (18)
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
- Ovarian, uterine, and cervical cancer in the elderly woman. (1993) (18)
- History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report (2017) (18)
- Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. (2018) (17)
- Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. (2015) (17)
- Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers (2012) (16)
- Transcriptome-wide association study of breast cancer risk by estrogen-receptor status (2020) (16)
- Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK (2011) (16)
- Biopsychological stress factors in BRCA mutation carriers. (2012) (16)
- Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene (2017) (16)
- Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers (2019) (15)
- FOXC2 augments tumor propagation and metastasis in osteosarcoma (2016) (15)
- A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (15)
- Advanced-stage ovarian carcinoma presenting during infertility evaluation. (1994) (15)
- Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube. (2021) (15)
- Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas (2014) (15)
- Activation of the MEK–S6 Pathway in High-grade Ovarian Cancers (2010) (15)
- Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17 q 21 . 31 (2013) (14)
- STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube. (2018) (14)
- Diagnosing the Correct Ovarian Cancer Syndrome (1991) (14)
- A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. (2013) (14)
- Conservative and Individualized Surgery for Early Squamous Carcinoma of the Vulva: The Treatment of Choice for Stage I and II (T1–2 N0–1 M0) Disease (1994) (14)
- Ovarian cancer symptoms speak out--but what are they really saying? (2010) (13)
- Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. (2015) (13)
- Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer (2007) (13)
- A Role for BRCA 1 in Uterine Leiomyosarcoma (2009) (13)
- Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine. (2016) (13)
- Sexual harassment in the work place: Its impact on gynecologic oncology and women's health. (2018) (13)
- The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first‐degree relative with breast cancer (2018) (13)
- Perioperative coagulopathy in patients undergoing primary cytoreduction (1993) (13)
- Single-cell Transcriptomics Identifies Gene Expression Networks Driving Differentiation and Tumorigenesis in the Human Fallopian Tube (2020) (12)
- Language as a barrier to cancer clinical trial accrual: assessing consenting team knowledge and practices for cancer clinical trial consent among low English fluency patients (2018) (12)
- Metformin induces distinct bioenergetic and metabolic profiles in sensitive versus resistant high grade serous ovarian cancer and normal fallopian tube secretory epithelial cells (2017) (12)
- Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study. (2015) (12)
- Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (12)
- Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources: Committee on Government Reform United States House of Representatives. (2005) (12)
- Current role of ultrasound in ovarian cancer screening. (1996) (12)
- Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers. (2010) (12)
- Aspirin use correlates with survival in women with clear cell ovarian cancer (2018) (12)
- Identification of novel epithelial ovarian cancer loci in women of African ancestry (2020) (12)
- Surgery for Ovarian Cancer: Principles and Practice (2005) (12)
- Early detection and risk reduction for familial gynecologic cancers. (1998) (12)
- The etiology and management of diarrhea in the gynecologic oncology patient. (1993) (12)
- The CYP 1 A 2 Genotype Modifies the Association Between Coffee Consumption and Breast Cancer Risk Among BRCA 1 Mutation Carriers (2007) (12)
- Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. (2014) (11)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
- Androgens and epithelial ovarian cancer: What's the connection? (2008) (11)
- Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. (2016) (11)
- A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes (2021) (10)
- Integrated Molecular Profiling Studies to Characterize the Cellular Origins of High-Grade Serous Ovarian Cancer (2018) (10)
- A scalable filtration method for high throughput screening based on cell deformability. (2019) (10)
- The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection? (2007) (10)
- Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells. (1989) (10)
- The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant (2021) (10)
- Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration (2016) (10)
- Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. (2007) (10)
- Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers (2019) (10)
- Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer (2014) (10)
- Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility (2018) (9)
- Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. (2018) (9)
- Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2016) (9)
- Ultrasound guided transversus abdominis plane (TAP) block utilization in multimodal pain management after open gynecologic surgery (2018) (9)
- Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium (2011) (9)
- Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis. (2016) (9)
- Ophira M. GinsburgCharmaine Kim-SingWilliam D. Foulkes • Parviz GhadirianHenry T. LynchPing SunSteven A. Narod • Hereditary Breast Cancer Clinical Study Group (2010) (9)
- Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers (2012) (9)
- Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes (2019) (9)
- Evolving Paradigms in Research and Care in Ovarian Cancers. (2016) (9)
- Impact of Beta Blockers on Epithelial Ovarian Cancer Survival (2013) (9)
- Effect of cigarette smoking on epithelial ovarian cancer survival. (2010) (8)
- Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia (2015) (8)
- Simultaneous stimulation of urokinase and tissue‐type plasminogen activators by phorbol esters in human ovarian carcinoma cells (1989) (8)
- History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium (2017) (8)
- Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic/pharmacodynamic (PK/PD) modeling to facilitate phase III dose selection. (2010) (8)
- Planning for post‐pandemic cancer care delivery: Recovery or opportunity for redesign? (2020) (8)
- Dawn of a New Cover (2015) (7)
- PRO: Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening (2009) (7)
- Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary? (2020) (7)
- Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? (2015) (7)
- Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics (2017) (7)
- Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis (2021) (7)
- Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. (2020) (7)
- A novel clinical trial recruitment strategy for women's cancer. (2014) (7)
- Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers (2020) (7)
- A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial. (2014) (6)
- Danforth Obstetrics and Gynecology 10Ed (2008) (6)
- Discussion: Hereditary Ovarian Cancer (2003) (6)
- Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations (2020) (6)
- Post treatment surveillance of type II endometrial cancer patients. (2013) (6)
- Non-coding Somatic Mutations Converge on the PAX8 Pathway in Epithelial Ovarian Cancer (2019) (5)
- Contemporary progress in ovarian cancer screening (2007) (5)
- Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model (2020) (5)
- Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies. (2005) (5)
- Molecular signatures of ovarian cancer: from detection to prognosis. (2010) (5)
- Surgical advances in the treatment of ovarian cancer. (2003) (5)
- Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. (2020) (5)
- Hormone replacement therapy and the risk of ovarian cancer in BRCA 1 and BRCA 2 mutation carriers (2005) (5)
- HOXB13 controls cell state through super-enhancers. (2020) (5)
- Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes (2022) (5)
- Phase II trial of pembrolizumab with cisplatin and gemcitabine in women with recurrent platinum-resistant ovarian cancer (2019) (5)
- Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women (2019) (5)
- Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer (2020) (5)
- DNA Methylation Profiles of Ovarian Clear Cell Carcinoma (2021) (5)
- rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology (2018) (4)
- Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. (2015) (4)
- Functional domains of CCN 1 ( Cyr 61 ) regulate breast cancer progression (4)
- Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes (2022) (4)
- Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial (2020) (4)
- Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma (2022) (4)
- PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine. (2021) (4)
- A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants (2019) (4)
- A gene expression profile of BRCAness that correlates with responsiveness to platinum and PARP inhibitors. (2010) (4)
- Correction: Comparison of Breast Cancer to Healthy Control Tissue Discovers Novel Markers with Potential for Prognosis and Early Detection (2010) (4)
- Early results from the BRCA Founder Outreach (BFOR) Study: Population genetic screening using a medical model. (2019) (4)
- Correction: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer (2016) (4)
- Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers? (2020) (4)
- MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma (2021) (4)
- Screening for familial ovarian cancer (2000) (4)
- Genetic aspects of ovarian cancer (1994) (4)
- Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
- Dawn of a new era for Gynecologic Oncology (2008) (3)
- No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival (2016) (3)
- Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer (2016) (3)
- Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. (2017) (3)
- Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection (2010) (3)
- Reply to W.R. Robinson (2012) (3)
- Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers (2021) (3)
- Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. (2021) (3)
- Efforts towards erasing borders in gynecologic cancer? (2017) (3)
- False-Positive Screening Events and Worry Influence Decisions About Surgery Among High-Risk Women (2019) (3)
- Molecular advances in gynecologic oncology. (1999) (3)
- Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers (2021) (3)
- Identification of predictive markers of clinical activity from a phase II trial of single agent pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer (OC). (2006) (3)
- Secondary cytoreductive surgery (2010) (3)
- Sexual Harassment in the Work Place: Its Impact on Gynecologic Oncology and Women's Health (2018) (3)
- Title Sphingosine kinase 1 is required for TGF-beta mediated fibroblast-to-myofibroblast differentiation in ovarian cancer (2016) (3)
- Hereditary ovarian cancer (2003) (2)
- Abstract A39: COL11A1 is a regulator of tumor microenvironment and a biomarker of metastatic progression (2015) (2)
- Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer (2021) (2)
- Glasgow Prognostic Score Associated with Lower Rates of R0 Cytoreduction in Women with Stage III Serous Ovarian Cancer (2016) (2)
- Differential expression of ASS1 in serous and non‐serous ovarian carcinomas (2014) (2)
- Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism (2014) (2)
- 21 Code of Federal Regulations Part 11-Compliant Digital Signature Solution for Cancer Clinical Trials: A Single-Institution Feasibility Study. (2020) (2)
- Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer (2020) (2)
- Differential Gene Expression between Normal and Tumor-derived Ovarian Epithelial Cells 1 (2000) (2)
- Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers (2020) (2)
- Stage IV ovarian carcinoma following ovulation induction: a report of three cases (1997) (2)
- Abstract 329: A mouse model of epithelial ovarian cancer with defined oncogenic drivers. (2013) (2)
- Concurrent interstitial radiotherapy and infusional chemotherapy for recurrent gynecologic malignancies (1992) (2)
- Evolution through intelligent design. (2006) (2)
- Before and after GOG 99: Did our practice patterns for treatment of intermediate risk endometrial adenocarcinoma change? (2010) (2)
- History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium (2017) (2)
- Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci (2017) (2)
- Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated truncating mutations in BRCA1 and BRCA2 genes lead to increased baseline genetic instability and diminished growth in fallopian tube epithelial cell line (2019) (2)
- CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis (2022) (2)
- Common variants at the CHEK 2 gene locus and risk of epithelial ovarian cancer (2015) (2)
- Peri-operative ketorolac is associated with improved epithelial ovarian cancer survival (2012) (2)
- Surgery for Ovarian Cancer (2019) (2)
- Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (1)
- Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. (2015) (1)
- Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ Mutation Carriers (2016) (1)
- The Fragile HistidineTriad Gene : AMolecular Link Between Cigarette Smoking and Cervical Cancer (2005) (1)
- PD-1/PD-L1 expression in mutated ovarian cancers (2019) (1)
- Syddansk Universitet Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12 p 11 locus (2016) (1)
- Platelets reduce anoikis and promote metastasis by activating YAP1 signaling (2017) (1)
- Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium (2020) (1)
- Bone density testing underutilized in BRCA population following risk-reducing salpingo-oophorectomy (2016) (1)
- Selected abstracts submitted to the Third International Symposium on Hereditary Breast and Ovarian Cancer (2009) (1)
- Cancer esearch cular and Cellular Pathobiology A 1-Associated Epigenetic Regulation of p 73 Mediates an R ctor Pathway for Chemosensitivity in Ovarian Carcinoma (2010) (1)
- Exposure-response relationship of open-label (OL) AMG 386 monotherapy in patients (pts) with recurrent ovarian cancer. (2012) (1)
- PD-1 and PD-L1 staining patterns in cervical squamous cell carcinoma (2016) (1)
- Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
- 15-Hydroxyprostaglandin dehydrogenase (PGDH) is an aberrant tumor suppressor in human breast cancer. (2006) (1)
- Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy? (2019) (1)
- XPC single-nucleotide polymorphisms correlate with prolonged progression-free survival in advanced ovarian cancer (2011) (1)
- Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: a Reappraisal. (2022) (1)
- Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression (2022) (1)
- Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (1)
- What drives the development of synchronous endometrioid endometrial and ovarian cancers (2013) (1)
- Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium (2017) (1)
- Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma (2022) (1)
- Abstract 2752: Genetic heterogeneity of ovarian cancer survival effects inBRCA1/2germline mutations: a large, multi-center study (2011) (1)
- Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers (2015) (1)
- The BRCA founder outreach study: Initial results of a digital health model. (2020) (1)
- Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (1)
- Abstract B48: Targeting chemo-resistance in CCNE1-amplified ovarian cancer (2013) (1)
- Occult cancers at risk-reducing salpingo-oophorectomies (RRSO) in BRCA mutation carriers (2012) (1)
- Aspirin Use Correlates with Survival in Women with Clear Cell Cancers of the Ovary (2017) (1)
- Suboptimal Cytoreduction in Ovarian Carcinoma Is Associated with Molecular Pathways Characteristic of Increased Stromal Activation (2016) (1)
- Multi-Tissue Transcriptome-Wide Association Study Identifies 26 Novel Candidate Susceptibility Genes for High Grade Serous Epithelial Ovarian Cancer (2018) (1)
- Language as a barrier to cancer clinical trial accrual: Assessing consenting team knowledge (2016) (1)
- Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers (2022) (1)
- Metformin and phenformin inhibit cell proliferation and alter metabolism in high-grade serous ovarian cancer (HGSC) (2017) (1)
- Utilizing Eastern Cooperative Oncology Group (ECOG) performance status scores to prevent harm with chemotherapy at the end of life. (2014) (1)
- Can lifestyle influence genetics? (2007) (1)
- Activated stromal mast cells in high grade serous ovarian cancers (HGSC) are associated with poor overall survival (2016) (1)
- Abstract 1749: Cell cycle requirements shape ovarian cancer progression. (2013) (1)
- Impact of Timing of Diagnosis on Clinical Outcome of Placenta Accreta (2003) (1)
- Abstract B09: Sphingosine kinase 1 (SPHK1) is a novel mediator of tumor-stroma interaction in ovarian cancer (2015) (1)
- Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study (2022) (1)
- Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers (2022) (1)
- Too much, too late: Aggressive care in women with recurrent gynecologic malignancies and the ttiming of end-of life discussions (2013) (1)
- Abstract B64: Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. (2016) (1)
- FOXC2 Promotes Vasculogenic Mimicry in Ovarian Cancer (2022) (1)
- Serum interleukin-6 is a biomarker of survival in women with advanced stage and optimally resected epithelial ovarian cancer (2015) (1)
- CAG Polymorphisms in androgen signaling genes predict aggressive epithelial ovarian cancer biology (2006) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Factors associated with high-cost hospitalizations in elderly ovarian cancer patients. (2020) (1)
- Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers (2019) (1)
- Genomic characterization of grade 3 endometrial carcinoma (2014) (1)
- Prophylactic Bilateral Salpingo-Oophorectomy May Leave Residual Fallopian Tube (2007) (1)
- ACollagen-Remodeling Gene Signature Regulated by TGF-b Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer (2014) (1)
- 0299: Are There Medical Co-Morbidities that Predict the Feasibility of Cytoreductive Surgery in Patients with Advanced Ovarian Cancer? (2006) (0)
- The Devil is in the Details (2008) (0)
- Patterns of care for risk-reducing salpingo-oophorectomy (RRSO) for BRCA mutation carriers and subsequent surveillance (2013) (0)
- Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (0)
- Undifferentiated endometrial adenocarcinoma: Treatment and characteristics of a rare disease (2019) (0)
- Abstract 725: Feasibility and evaluation of exosomal RNAs as novel diagnostic biomarkers for high grade serous epithelial ovarian cancer (2017) (0)
- Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | NOVA. The University of Newcastle's Digital Repository (2014) (0)
- Histopathological characterization of the tubal fimbria reveals a subgroup of BRCA1 mutation carriers with tumor-promoting gene-set enrichment (2020) (0)
- BRCA mutation carriers: Risk factors for psychosocial and physiologic disruption. (2011) (0)
- heterozygous truncating mutations lead to phenotypic changes in CRISPR/Cas9 mutated fallopian tube secretory epithelial cells (2019) (0)
- Abstract 1906: FOXC1 regulates cancer stem cells properties via inducing SMO-independent Gli activation and confers anti-Hedgehog drug resistance in basal-like breast cancer (2014) (0)
- Evaluating exosome proteins as biomarkers for the early detection of high-grade serous ovarian cancer (2018) (0)
- Male breast cancer in BRCA1 and BRCA2 mutation carriers (2018) (0)
- 0168: Whole Genome Copy Number Analysis of Advanced Ovarian Cancer Identifies Patterns Associated with Prolonged Survival (2006) (0)
- Abstract GMM-042: PAN-CANCER TRANSCRIPTION FACTOR ANALYSES IDENTIFY ZNF217 AS A NOVEL DRIVER IN HGSOC (2019) (0)
- Abstract AS13: Epidemiologic predictors of pre-treatment CA125 in women with ovarian cancer (2015) (0)
- A Web-based Information System Supporting Gynecologic Oncology Translational Research (2001) (0)
- Genetic Differences Between BRCA-Associated and Sporadic Ovarian Cancer DNA (2007) (0)
- Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer (2016) (0)
- Author reply (0)
- Risk of breast cancer following ovarian cancer and the impact on overall survival (2014) (0)
- Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative study (2021) (0)
- Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2020) (0)
- Mast cells are a newly identified immune component of the mesenchymal subtype in high-grade serous ovarian cancer (HGSC) (2017) (0)
- Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (0)
- DNA methylation landscapes of matched primary and recurrent high grade serous ovarian cancers are preserved throughout disease progression and chemoresistance (2020) (0)
- STAT3/PIAS3 as 'early signature' gene pathways in the development of ovarian high-grade serous carcinoma from the fallopian tube (2016) (0)
- Original Research Reports Biopsychological Stress Factors in BRCA Mutation Carriers (2012) (0)
- Patterns of risk reducing surgery in germline homologous recombination deficiency/non-BRCA mutation carriers (2019) (0)
- Variation in NFk B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer (2014) (0)
- Enhancing chemotherapy for ovarian, breast and brain cancers by targeting protein translation with RNA interference (2007) (0)
- 970O CARBOPLATIN PLUS PACLITAXEL VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN AS FIRST- LINE TREATMENT FOR PATIENTS WITH OVARIAN CANCER: THE MITO-2 (MULTICENTRE ITALIAN TRIALS IN OVARIAN CANCER) RANDOMIZED PHASE III TRIAL (2010) (0)
- Mole BRC Effe (2010) (0)
- Predictive efficacy of proapoptotic epigenetic pharmacotherapies: An ovarian cancer paradigm (2006) (0)
- Brachytherapy versus external beam radiation therapy in high intermediate risk endometrial cancer patients (2008) (0)
- Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (0)
- 353 - Poster Session BA novel clinical trial recruitment strategy for women's cancers (2014) (0)
- Vaginal High-Grade Sarcoma in Pregnancy (2021) (0)
- Antibiotic Use Negatively Influences Survival in Epithelial Ovarian Cancer: A Case for Studying the Microbiome (2016) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- The clinicopathologic significance of FOXC1 in BRCA-mutant breast cancer. (2014) (0)
- Abstract PO023: Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube (2021) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Abstract 1511: Stromal gene signature regulated by TGFβ signaling predicts poor clinical outcome in ovarian cancer . (2013) (0)
- BRCA1 expression is downregulated in uterine leiomyosarcomas (2010) (0)
- Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci (2022) (0)
- Breast cancer following ovarian cancer in BRCA mutation carriers: What is the cost of surveillance? (2014) (0)
- Liver X receptor (LXR) as a target for ovarian cancer (2008) (0)
- Frequency of serous tubal intraepithelial carcinomas in primary peritoneal serous carcinomas (2015) (0)
- Identification of gynecologic oncology patients that can be fast-tracked for early discharge (2012) (0)
- Characteristics of primary peritoneal serous carcinoma in a U.S. population enriched for Jewish ancestry (2016) (0)
- A randomized study of cash cards versus checks as clinician survey incentives (2020) (0)
- Improving efficiencies in translational science. (2008) (0)
- Relationship between Body Mass Index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project (2015) (0)
- Disparities in palliative care utilization and outcomes during inpatient hospitalization for gynecologic malignancies in the United States, 2009–2018 (2022) (0)
- p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study (2023) (0)
- Occult and subsequent gynecologic cancers following risk-reducing salpingo-oophorectomies (RRSO) in BRCA mutation carriers (2014) (0)
- Elevated serum adiponectin levels correlate with survival in epithelial ovarian cancers (2011) (0)
- High prevalence of primary peritoneal serous carcinoma among Jewish BRCA mutation carriers may limit the efficacy of screening ultrasound for early detection (2012) (0)
- Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (0)
- Interval Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer (1996) (0)
- Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA (2013) (0)
- Post treatment surveillance of type II endometrial cancer survivors (2012) (0)
- A history of breast carcinoma predicts worse survival in BRCA1 and BRCA2 mutation carriers with ovarian carcinoma (2011) (0)
- PD-1 and PD-L1 Expression in Advanced Endometrial Adenocarcinoma (2016) (0)
- Risk factors for recurrent high grade vaginal intraepithelial neoplasia and progression to carcinoma (2014) (0)
- DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers (2022) (0)
- University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch, (2013) (0)
- Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer (2014) (0)
- THE ROLE OF REASSESSMENT LAPAROSCOPY IN MANAGING OVARIAN CANCER (1998) (0)
- [Is ultrasound screening for ovarian cancer possible in 1998?]. (1998) (0)
- No Association of the I1307K APC AlÃelewith Ovarian Cancer Risk in (1998) (0)
- Primary peritoneal carcinoma surveillance practices following risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers (2016) (0)
- Abstract 3880: The natural dietary phytochemical indole-3-carbinole (I3C) sensitizes ovarian cancer cells to the proteasome inhibitor bortezomib through inhibition of cyclin E activity (2010) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Gynecologic Oncology 2017 Update: New Features and Expanded Scope. (2017) (0)
- Abstract IA11: Using publicly available databases for the functional characterization of cancer genes (2013) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer (2015) (0)
- Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (0)
- Profiling the perpetrator. (2004) (0)
- Abstract A30: Super-enhancer-associated long noncoding RNA UCA1 interacts directly with AMOT to inhibit Hippo signaling pathway in epithelial ovarian cancer (2020) (0)
- Corrigendum to “A novel clinical trial recruitment strategy for women's cancer” [Gynecol. Oncol. 138 (2015) 445–448] (2015) (0)
- University of Groningen DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers Osorio, (2014) (0)
- Modified viral capsid protein mediates non-viral targeting of unique non-covalent drug conjugates to HER2+ breast cancer cells. (2007) (0)
- PW238 Heart Disease and Breast Cancer Survivorship: A Cardio-Oncology Quality Improvement Initiative (2014) (0)
- Comprar Obstetricia y Ginecologia de Danforth | Ingrid E. Nygaard MD | 9788496921320 | Lippincott Williams & Wilkins (2009) (0)
- Abstract A26: Molecular analysis of short- vs. long-term ovarian cancer survivors (2020) (0)
- Influence of residual disease and extreme drug resistance assays on outcome in patients with epithelial ovarian cancer. (2009) (0)
- Missense variants in Lynch Syndrome genes in endometrial cancer patients characterized by The Cancer Genome Atlas (TCGA) project. (2015) (0)
- Abstract 225: Tumor-infiltrating CD8-positive T-lymphocytes in tubo-ovarian high-grade serous cancer are associated with multiple germline variants in 22q12.1 in a genome-wide association analysis (2018) (0)
- Molecular Signatures of Ovarian Cancer (2012) (0)
- Genetic Definition and Phenotypic Determinants of Human Ovarian Carcinomas (2001) (0)
- DNA Methylation Pro fi les of Ovarian Clear Cell Carcinoma (2021) (0)
- Abstract POSTER-BIOL-1348: No association between PARK2 and BRCA1-associated gynecologic cancers (2015) (0)
- CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2022) (0)
- Serous tubal intraepithelial carcinoma lesions are common in primary peritoneal serous carcinomas (2016) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Distinguishing primary mucinous ovarian carcinomas from primary gastrointestinal carcinomas metastatic to the ovaries: Are we trying hard enough and does it matter? (2008) (0)
- Abstract 586: Genomic and functional characterizations of phosphodiesterase 4Din human cancers. (2013) (0)
- Patterns of breast cancer surveillance and breast cancer detection in women with serous ovarian/tubal or peritoneal carcinomas who have had brca mutation testing (2013) (0)
- Breast cancer surveillance following ovarian cancer in mutation carriers (2019) (0)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
- Abstract IA20: Biomarkers for risk prediction, screening, and early diagnostics. (2016) (0)
- Gynecologic Oncology: Update 2012 (2012) (0)
- Does digoxin improve ovarian cancer survival by inducing immunogenic cell death? A SEER–Medicare database analysis (2015) (0)
- Special Interest Session III: Resident, Fellow, Candidate Session (2017) (0)
- Abstract LB-130: STAT3/PIAS3 as “early signature” gene pathways in the development of ovarian high grade serous carcinoma from the fallopian tube (2016) (0)
- Abstract 2726: Salivary biomarkers for breast cancer detection (2010) (0)
- Gynecologic health surveillance and outcomes in BRCA mutation carriers following risk-reducing salpingo-oophorectomy (2016) (0)
- Abstract 2615: Systematic approaches to predict oncogenic transcriptional regulatory circuitries identify important nodes in high-grade serous ovarian cancer (2019) (0)
- Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer (2016) (0)
- A KRAS hot spot mutation correlates with MLH1 methylation in endometrial carcinomas with microsatellite instability: A potential triage tool for Lynch syndrome evaluation (2014) (0)
- Plasminogen activator secretion by 10 human ovarian carcinoma cell lines in vitro (1988) (0)
- 0037: Alterations of the Tumor Suppressor Gene Fhit in Vulvar Cancer Related to Cigarette Smoking and Reduced Disease-Specific Survival (2006) (0)
- Chapter 7 – Ovarian Cancer Surgery (2010) (0)
- Somatic reversion mutations in hereditary ovarian carcinomas predict platinum sensitivity (2018) (0)
- Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium (2017) (0)
- Cancer screening distress in a clinic-based population of BRCA mutation carriers (2008) (0)
- Abstract 5443: FOXC1 is a critical mediator of EGFR function in basal-like breast cancer. (2013) (0)
- Predictors of residual disease at hysterectomy following cervical conizations with positive margins (2012) (0)
- preclinical validation of salivary proteomic biomarkers for the non-invasive detection of breast cancer. (2010) (0)
- Hormonal therapies demonstrate high response rates in treatment of recurrent uterine sarcomas (2008) (0)
- FAMILIAL CANCER SYNDROMES (1998) (0)
- Single nucleotide polymorphism in MDM2 is associated with sporadic endometrial cancer risk. (2006) (0)
- The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (0)
- Abstract #1352: ROR1 amplification and overexpression in ovarian cancer (2009) (0)
- serous ovarian cancer signaling is associated with metastasis and poor survival in β A collagen-remodeling gene signature regulated by TGF (2013) (0)
- The identification and validation of exosome proteins as biomarkers for high-grade serous ovarian cancer (2019) (0)
- Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. (2022) (0)
- Oxidized low density lipoprotein (LDL) stimulates ovarian carcinoma proliferation that is inhibited by the LXR agonist T0901317 (2007) (0)
- Abstract #4437: BRCA1 expression is downregulated in uterine leiomyosarcomas (2009) (0)
- Abstract 2248: Environmental factors associated with residual disease after ovarian cancer primary cytoreduction surgery (2022) (0)
- Morbidity of triple modality therapy in the management of early stage cervical cancer (2014) (0)
- Shared heritability and functional enrichment across six solid cancers (2019) (0)
- Antibiotics and the commensal microbiota: Impact on survival in women with epithelial ovarian cancer (2016) (0)
- Abstract 1088: HOXB13 inhibition of succinate dehydrogenase leads to epithelial-to-mesenchymal transition in mouse ovarian cancer cell lines. (2013) (0)
- Outcomes with ultrasound guided transversus abdominal plane (TAP) block after open gynecologic surgery (2018) (0)
- Abstract 5435: Role of the WT1 transcription factor in high-grade serous ovarian cancer (2018) (0)
- Risk of diminished ovarian reserve in BRCA 1/2 mutation carriers (2013) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Abstract MIP-060: EPIGENETIC DYSREGULATION OF A HISTONE MARK REVEALS A METABOLIC VULNERABILITY IN OVARIAN CANCER (2017) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. (2023) (0)
- The role of FOXC1 in clear cell ovarian carcinoma: Potential prognostic biomarker for aggressive disease? (2015) (0)
- Growth , and Morphological Alterations Carcinoma Cells : Inhibition of Plasminogen Activators , Cell Glucocorticoid Sensitivity of OVCA 433 Human Ovarian Updated (2006) (0)
- Abstract POSTER-CTRL-1213: Whole exome and targeted resequencing, of population based ovarian cancer cases and controls, identifies susceptibility genes for ovarian cancer (2015) (0)
- Abstract 5077: Molecular profiling in recurrent ovarian cancer patients: Considerations for the design of clinical studies to validate profiling for therapy selection (2011) (0)
- Quality of care in advanced ovarian cancer: How important is provider specialty? (2016) (0)
- Author reply (2007) (0)
- Abstract AP23: EARLY LOSS OF MONOUBIQUITYLATION OF HISTONE H2B ALTERS KEY IMMUNE SIGNALING PATHWAYS PROMOTING THE PROGRESSION OF HIGH-GRADE SEROUS OVARIAN CANCER (2019) (0)
- Secondary BRCA1/2 mutations are associated with platinum resistance in BRCA1/2-mutated ovarian carcinomas (2010) (0)
- Abstract TMEM-026: ZEB1–MEDIATED NNMT EXPRESSION ELICITS PHENOTYPIC AND METABOLIC PLASTICITY OF OVARIAN CANCER CELLS UNDER NUTRITIONAL STRESS (2017) (0)
- Lack of genomic predictors of recurrence in uterine carcinoma (2014) (0)
- Abstract 809: Selecting ovarian cancer patients for clinical trials using a broad panel of molecular markers (2010) (0)
- The colon is a pelvic organ too: taking the Couric challenge. (2004) (0)
- Erratum: Xeroderma pigmentosum complementation group C single‐nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression‐free survival in advanced ovarian cancer (2012) (0)
- The CROWN initiative: journal editors invite researchers to develop core outcomes in women's health. (2014) (0)
- The effect of body mass index on the molecular landscape of endometrial cancer (2021) (0)
- Abstract 395: Identifying the functional drivers of noncoding somatic mutations in ovarian cancer (2018) (0)
- Co-culture of human induced pluripotent stem cells (iPSCs) with human fallopian tube epithelium (FTE) induces Pax8 and CK7 expression: Initial steps in modeling fallopian tube epithelium to study serous carcinogenesis (2015) (0)
- Serum interleukin-6 is a biomarker of outcome in women with advanced stage optimally resected ovarian cancer (2015) (0)
- 201: The aging suppressor hormone klotho: A novel tumor suppressor and regulator of estrogen signaling in ovarian cancer (2014) (0)
- Distinct early changes in the fallopian tubes of mutation carriers (2019) (0)
- An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (0)
- Abstract AP11: IDENTIFYING FUNCTIONAL NONCODING SOMATIC MUTATIONS IN OVARIAN CANCER (2019) (0)
- Abstract 4407: Neutralizing monoclonal antibody to periostin (PN) inhibits ovarian tumor metastatic growth in animal models (2010) (0)
- DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers (2022) (0)
- q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers (2012) (0)
- Obesity correlates with overall survival in women with recurrent epithelial ovarian cancer (2013) (0)
- The prognostic significance of ADAM metallopeptidase domain 12 in advanced stage serous ovarian cancer (2014) (0)
- Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (0)
- Dual targeting of and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model. (2020) (0)
- Abstract B44: Early loss of monoubiquitylation of H2B alters key metabolic and immune signaling pathways promoting the progression of high-grade serous ovarian cancer (2018) (0)
- PI3K pathway activation, thromboembolism and survival in ovarian clear cell carcinoma (2013) (0)
- Abstract 678: The Ets factor ETV5 regulates E2F target genes and mediates drug resistance (2014) (0)
- Surveillance and health outcomes for BRCA mutation carriers following risk-reducing salpingo-oophorectomy (RRSO) (2015) (0)
- Association of breast cancer risk in BRCA 1 and BRCA 2 mutation carriers with genetic variants showing differential allelic expression (2016) (0)
- Peak Postoperative Glucose Levels Predict Complications After Primary Cytoreductive Surgery for Advanced Ovarian Cancer (2007) (0)
- Risk of Uterine Cancer in Women with Deleterious BRCA Mutations Who Undergo Risk Reducing Salpingo-oophorectomy (RRSO) (2017) (0)
- Expression profiles in matched primary and recurrent serous ovarian carcinomas. (2011) (0)
This paper list is powered by the following services:
Other Resources About Beth Karlan
What Schools Are Affiliated With Beth Karlan?
Beth Karlan is affiliated with the following schools:
